Top 5 Most Read RNS's on Vox Markets for Wednesday 7th September 2022
Episode 877, Sep 07, 2022, 06:53 AM
5. i3 Energy #I3E October 2022 Dividend Declaration
i3 announces its monthly dividend totalling £1.6996 million and confirms the following:
Dividend: 0.1425 pence/share
(Click here to read the RNS)
4. Union Jack Oil #UJO - Half-year Report 2022
Maiden profit of £2,034,086 for the six-month period ended 30 June 2022
(Click here to read the RNS)
3. Premier African Minerals #PREM Zulu Assay Results and Pilot Plant Update
Assay results at Premier's Zulu Lithium and Tantalum Project continue to support their decision to proceed with the pilot plant and at the same time will be incorporated into the revised Mineral Resource update required to support the DFS.
(Click here to read the RNS)
2. Kistos PLC #KIST Interim results
Revenue increasing by +745% €285m
(Click here to read the RNS)
1. Synairgen plc #SNG Positive Findings from SG015 Tri-al Analysis
positive data from additional assessments of lung sputum samples from its Phase 2 clinical trial of inhaled SNG001 in Chronic Obstructive Pulmonary Disease (COPD) patients with a confirmed respiratory viral infection (SG015, NCT03570359).
(Click here to read the RNS)
i3 announces its monthly dividend totalling £1.6996 million and confirms the following:
Dividend: 0.1425 pence/share
(Click here to read the RNS)
4. Union Jack Oil #UJO - Half-year Report 2022
Maiden profit of £2,034,086 for the six-month period ended 30 June 2022
(Click here to read the RNS)
3. Premier African Minerals #PREM Zulu Assay Results and Pilot Plant Update
Assay results at Premier's Zulu Lithium and Tantalum Project continue to support their decision to proceed with the pilot plant and at the same time will be incorporated into the revised Mineral Resource update required to support the DFS.
(Click here to read the RNS)
2. Kistos PLC #KIST Interim results
Revenue increasing by +745% €285m
(Click here to read the RNS)
1. Synairgen plc #SNG Positive Findings from SG015 Tri-al Analysis
positive data from additional assessments of lung sputum samples from its Phase 2 clinical trial of inhaled SNG001 in Chronic Obstructive Pulmonary Disease (COPD) patients with a confirmed respiratory viral infection (SG015, NCT03570359).
(Click here to read the RNS)